Revisiting the duration of vasomotor symptoms of menopause: A meta-analysis

被引:153
|
作者
Politi, Mary C. [1 ]
Schleinitz, Mark D. [2 ]
Col, Nananda F. [3 ]
机构
[1] Brown Med Sch, Dept Behav & Prevent Med, Providence, RI 02903 USA
[2] Brown Med Sch, Dept Gen Int Med, Providence, RI 02903 USA
[3] Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA
关键词
D O I
10.1007/s11606-008-0655-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Treatment decisions about menopause are predicated on a transient duration of vasomotor symptoms. However, evidence supporting a specific duration is weak. OBJECTIVE: To estimate the natural progression of vasomotor symptoms during the menopause transition by systematically compiling available evidence using meta-analytic techniques. DATA SOURCES: We searched MEDLINE, hand searched secondary references in relevant studies, book chapters, and review papers, and contacted investigators about relevant published research. REVIEW METHODS: English language, population-based studies reporting vasomotor symptom prevalence among women in menopausal transition in time intervals based on years to or from final menstrual period were included. Two reviewers independently assessed eligibility and quality of studies and extracted data for vasomotor symptom prevalence. RESULTS: The analyses included 10 studies (2 longitudinal, 8 cross sectional) with 35,445 participants. The percentage of women experiencing symptoms increased sharply in the 2 years before final menstrual period, peaked 1 year after final menstrual period, and did not return to premenopausal levels until about 8 years after final menstrual period. Nearly 50% of all women reported vasomotor symptoms 4 years after final menstrual period, and 10% of all women reported symptoms as far as 12 years after final menstrual period. When data were examined according to symptom severity ('any' vs. 'bothersome'), bothersome symptoms peaked about 1 year earlier and declined more rapidly than symptoms of any severity level. CONCLUSIONS: Our findings suggest a median symptom duration of about 4 years among symptomatic women. A longer symptom duration may affect treatment decisions and clinical guidelines. Further prospective, longitudinal studies of menopausal symptoms should be conducted to confirm these results.
引用
收藏
页码:1507 / 1513
页数:7
相关论文
共 50 条
  • [1] Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis
    Mary C. Politi
    Mark D. Schleinitz
    Nananda F. Col
    [J]. Journal of General Internal Medicine, 2008, 23 : 1507 - 1513
  • [2] Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
    Chavez, Matheus Pedrotti
    Pasqualotto, Eric
    Ferreira, Rafael Oliva Morgado
    Hohl, Alexandre
    de Moraes, Francisco Cezar Aquino
    Schmidt, Pedro Henrique Siedschlag
    Rodrigues, Anna Luiza Soares de Oliveira
    de Sa, Joao Roberto
    [J]. CLIMACTERIC, 2024, 27 (03) : 245 - 254
  • [3] Fezolinetant Compared With Placebo for Vasomotor Symptoms in Menopause: A Systematic Review and Meta-Analysis
    Dias, Yasmin Jardim Meirelles
    Almeida, Juliana Vieira Queiroz
    Novellino, Andrea Mora de Marco
    Eskandar, Karine
    Zotti, Ana Isabela de Araujo
    [J]. OBSTETRICS AND GYNECOLOGY, 2024, 143 (5S): : 19S - 19S
  • [4] Duration of menopausal vasomotor symptoms over the menopause transition
    Bond, Sharon
    You, Xiaolan
    [J]. JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2015, 60 (06) : 781 - 783
  • [5] Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
    Avis, Nancy E.
    Crawford, Sybil L.
    Greendale, Gail
    Bromberger, Joyce T.
    Everson-Rose, Susan A.
    Gold, Ellen B.
    Hess, Rachel
    Joffe, Hadine
    Kravitz, Howard M.
    Tepper, Ping G.
    Thurston, Rebecca C.
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (04) : 531 - 539
  • [6] Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis
    Elnaga, Ahmed A. Abo
    Alsaied, Mohamed A.
    Elettreby, Abdelrahman M.
    Ramadan, Alaa
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2024, 297 : 142 - 152
  • [7] VASOMOTOR SYMPTOMS IN MENOPAUSE AND CARDIOVASCULAR RISK FACTORS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Iliodromiti, S.
    Begbie, R.
    [J]. FERTILITY AND STERILITY, 2018, 110 (04) : E286 - E286
  • [8] Vasomotor Symptoms During Menopause
    Gorczyca M.
    [J]. Journal für Gynäkologische Endokrinologie/Österreich, 2021, 31 (2): : 79 - 81
  • [9] Managing the Vasomotor Symptoms of Menopause
    Ambizas, Emily M.
    Etzel, Joseph V.
    Maniara, Bejoy
    [J]. US PHARMACIST, 2016, 41 (09) : 8 - 11
  • [10] Vasomotor and Related Menopause Symptoms
    Stuenkel, Cynthia A.
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 2018, 61 (03): : 433 - 446